Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Period 1
Drug: Period 2

First Posted Date: 2011-03-18

Last Posted Date: 2012-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01318031

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: PF-03715455
Drug: Placebo for PF-03715455
Drug: Placebo for PH-797804
Drug: PH-797804

First Posted Date: 2011-03-15

Last Posted Date: 2012-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT01314885

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 3 mg PF-03882845
Drug: 10 mg PF-03882845
Drug: 30 mg PF-03882845
Drug: 100 mg PF-03882845
Drug: Spironolactone

First Posted Date: 2011-03-15

Last Posted Date: 2011-07-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01314898

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A-B
Drug: Treatment B-A

First Posted Date: 2011-03-14

Last Posted Date: 2011-06-28

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT01313793

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Smoking Cessation Study In Healthy Adolescent Smokers

Phase 4

Completed

Conditions: Smoking Cessation

Interventions: Drug: Varenicline 0.5mg BID
Drug: Placebo
Drug: Varenicline 1mg BID

First Posted Date: 2011-03-11

Last Posted Date: 2018-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 312

Registration Number: NCT01312909

Locations: 🇨🇦
Private Practice of Robert J. Camargo, Newmarket, Ontario, Canada
🇺🇸
Wake Internal Medicine Consultants, Inc, Raleigh, North Carolina, United States
🇺🇸
Dedicated Clinical Research, Goodyear, Arizona, United States

and more 75 locations

Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Myrin© 2 (Rifampicin + Isoniazid)
Drug: Rimactane® (Rifampicin)

First Posted Date: 2011-03-09

Last Posted Date: 2012-07-30

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT01311505

Locations: 🇵🇭
Pfizer Investigational Site, Dasmariñas City, Philippines

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Desvenlafaxine Succinate

First Posted Date: 2011-03-07

Last Posted Date: 2011-04-26

Lead Sponsor: Pfizer

Target Recruit Count: 1403

Registration Number: NCT01309542

Locations: 🇺🇸
Neurology & Neuroscience Center of Ohio, Toledo, Ohio, United States
🇫🇮
Turku Psychiatric Services Aurakatu 14 B 3 Krs, Turku, Finland
🇺🇸
The Medical Research Network, New York, New York, United States

and more 112 locations

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: CP-690,550
Drug: Placebo/CP-690,550

First Posted Date: 2011-03-07

Last Posted Date: 2014-09-19

Lead Sponsor: Pfizer

Target Recruit Count: 960

Registration Number: NCT01309737

Locations: 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸
InSight Diagnostic Center, Dallas, Texas, United States
🇨🇦
PerCuro Clinical Research Ltd, Victoria, British Columbia, Canada

and more 89 locations

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Phase 1

Completed

Conditions: Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular
Carcinoma, Squamous Cell of Head and Neck
Lymphoma, Non-Hodgkin
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Malignant Melanoma

Interventions: Drug: rituximab
Drug: PF-05082566

First Posted Date: 2011-03-02

Last Posted Date: 2020-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 190

Registration Number: NCT01307267

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC San Diego Moores Cancer Center-Investigational Drug Services, La Jolla, California, United States
🇺🇸
UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital), La Jolla, California, United States

and more 36 locations

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients

Terminated

Conditions: Breast Cancer

Interventions: Drug: Aromasin

First Posted Date: 2011-02-28

Last Posted Date: 2012-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 398

Registration Number: NCT01305239

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy